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Pharmaceutical tabletAbstract This article describes a gas chromatography–mass spectrometry (GC–MS) method for
the determination of ﬂurbiprofen in pharmaceutical preparations. The method is based on the
derivatization of ﬂurbiprofen with N-methyl-N-(trimethylsilyl)triﬂuoroacetamide (MSTFA). For
GC–MS, electron ionization mode (EI = 70 eV) and selected ion monitoring (SIM) mode were used
for quantitative analysis (m/z 180 for ﬂurbiprofen). Calibration curve was linear between the con-
centration range of 0.25–5.0 lg/mL. Intra- and inter-day precision values for ﬂurbiprofen were less
than 3.64, and accuracy (relative error) was better than 2.67%. The mean recovery of ﬂurbiprofen
was 99.4% for pharmaceutical preparations. The limits of detection and quantiﬁcation of ﬂurbipro-
fen were 0.05 and 0.15 lg/mL, respectively. No interference was found from tablet excipients at the
selected assay conditions. Also, the method was applied for the quality control of ﬁve commercial
ﬂurbiprofen dosage forms to quantify the drug and to check the formulation content uniformity.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are among
the most commonly prescribed agents worldwide to treat a
variety of pain-related conditions, including arthritis and other
rheumatic diseases. In addition, epidemiological studies have
shown that long-term use of NSAIDs reduces the risk of
developing Alzheimer’s disease and delays its onset(Townsend and Pratico, 2005; McGeer et al., 1996;
Cudaback et al., 2014).
Flurbiprofen is a non-steroidal anti-inﬂammatory agent,
one of the propionic acid group, which has signiﬁcant anti-
inﬂammatory, analgesic and antipyretic properties. Clinically,
it is used for the treatment of rheumatoid arthritis, degenera-
tive joint disease, osteoarthritis, ankylosing spondylitis, acute
musculoskeletal disorders, low back pain and allied conditions
(Murali Mohan Babu et al., 2002; Rousseau et al., 2008;
Muraoka et al., 2004; Uchino et al., 2014). It contains a ﬂuo-
rine atom in its molecular structure, producing better effects at
a lower therapeutic dose and with less adverse effects com-
pared with similar drugs.
Several methods have been reported for the determination
of ﬂurbiprofen including high performance liquid chromatog-
raphy (HPLC) (Rajani and Mukkanti, 2014; Albert et al.,
1984; Han et al., 2008; Chi et al., 1994; Johnson and Wilson,hemistry
2 B. Yilmaz, E. Alkan1986; Adams et al., 1987; Hutzler et al., 2000; Berry and
Jamali, 1988; Pe’hourcq et al., 2001; Geisslinger et al., 1992;
Knadler and Hall, 1989) and liquid chromatography–mass
spectrometry (LC–MS) (Mano et al., 2002). Over the last
20 years, several HPLC methods using UV or ﬂuorescence
detection have been reported for the estimation of ﬂurbiprofen
either alone or together with their metabolites in plasma/serum
(Albert et al., 1984; Askholt and Nielsen-Kudsk, 1986; Chi
et al., 1994; Johnson and Wilson, 1986; Adams et al., 1987;
Hutzler et al., 2000), in urine (Berry and Jamali, 1988;
Pe’hourcq et al., 2001; Geisslinger et al., 1992; Knadler and
Hall, 1989; Hirai et al., 1997) and in ocular ﬂuids (Riegel
and Ellis, 1994). USP 2000 (USP, 2000) and BP 1993 (BP,
1993) both have recommended HPLC method for analysis of
pure ﬂurbiprofen and in dosage form (tablet and ophthalmic
drops). Both the methods recommended use of a mobile phase
of acetonitrile–water–glacial acetic acid (60:35:5) at a ﬂow rate
of 1 mL/min. IP 1996 (IP, 1996) has suggested titrimetric
method for ﬂurbiprofen estimation.
There is no literature, which performed the determination
of ﬂurbiprofen in pharmaceutical preparations using MSTFA
as derivatization agent by GC–MS. Therefore, the present
work describes the O-silylation of the hydroxyl group of ﬂur-
biprofen using N-methyl-N-(trimethylsilyl)triﬂuoroacetamide
(MSTFA) as a silylating reagent. The method is validated with
respect to precision of peak response, linearity range, speciﬁc-
ity, accuracy, limit of detection (LOD) and limit of quantiﬁca-
tion (LOQ). Also, the proposed method is applied to the
analysis of ﬁve ﬂurbiprofen pharmaceutical preparations,
and the results are compared with USP 2000, BP 1993 and
IP 1996.
2. Experimental
2.1. Chemicals and reagents
Flurbiprofen (99.6% purity) was obtained from Sigma (St.
Louis, MO, USA). N-methyl-N-(trimethylsilyl)triﬂuoroaceta-
mide (MSTFA) and acetonitrile (99.8% purity) were pur-
chased from Sigma–Aldrich (St. Louis, MO, USA). Majezik,
Frolix, Maximus, Zero-P and Fortine tablets (100 mg ﬂurbi-
profen) were obtained from the pharmacy (Erzurum, Turkey).
2.2. Apparatus and analytical conditions
Chromatographic analysis was carried out on an Agilent
6890 N gas chromatography system equipped with 5973 series
mass selective detector, 7673 series autosampler and chemsta-
tion (Agilent Technologies, Palo Alto, CA). HP-5 MS column
with 0.25 lm ﬁlm thickness (30 m · 0.25 mm I.D., USA) was
used for separation. Splitless injection was used and the carrier
gas was helium at a ﬂow rate of 1 mL/min. The injector and
detector temperatures were 250 C. The MS detector parame-
ters were transfer line temperature 280 C, solvent delay 3 min
and electron energy 70 eV.
2.3. Preparation of stock solutions
Stock solution (1 mg/mL) of ﬂurbiprofen was prepared in
acetonitrile. The initial stock solution was further diluted inPlease cite this article in press as: Yilmaz, B., Alkan, E. Determination of ﬂurbipro
(2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.038acetonitrile to produce solutions of ﬂurbiprofen (10 lg/mL).
Calibration standards of ﬂurbiprofen at concentrations of
0.25–5 lg/mL (0.25, 0.5, 1, 2, 3, 4 and 5 lg/mL) were prepared
by spiking appropriate amount of the stock solution. Standard
solutions were stored at +4 C.
2.4. Preparation of quality control samples
The concentrations of ﬂurbiprofen were 0.75, 2.5 and 4.5 lg/mL
in acetonitrile to represent low, middle and high quality con-
trols, respectively. Appropriate volumes from stock solution
of ﬂurbiprofen were added to normal acetonitrile to get low,
middle and high quality control samples, respectively, and
stored at +4 C. The quality control samples were taken out
from storage for analysis to determine intra- and inter-day
precision and accuracy.
2.5. Procedure for pharmaceutical preparations
The average capsule mass was calculated from the mass of tab-
lets of Majezik, Frolix, Maximus, Zero-P and Fortine (100 mg
ﬂurbiprofen tablet, which was composed of ﬂurbiprofen and
some excipients). They were then ﬁnely ground, homogenized
and portion of the powder was weighed accurately, transferred
into a 100 mL brown measuring ﬂask and diluted to scale with
acetonitrile. The mixture was sonicated for at least 10 min to
aid dissolution and then ﬁltered through a Whatman 42 paper.
An appropriate volume of ﬁltrate was diluted further with ace-
tonitrile so that the concentration of ﬂurbiprofen in the ﬁnal
solution was within the working range and then analyzed by
GC–MS.
2.6. Data analysis
All statistical calculations were performed with the Statistical
Product and Service Solutions (SPSS) for Windows, version
10.0. Correlations were considered statistically signiﬁcant if
calculated P values were 0.05 or less.
3. Results
3.1. Method development and optimization
The method development for the assay of ﬂurbiprofen was
based on its chemical properties. The column and acquisition
parameters were chosen to be a starting point for the method
development. Flurbiprofen is a polar molecule. Therefore, the
capillary column coated with 5% phenyl and 95% dim-
ethylpolysiloxane is a good choice for separation of
ﬂurbiprofen.
The GC/MS parameters used in the method development
were based on the boiling point. The injection port and detec-
tor temperature was set to 250 C for GC–MS. Different tem-
perature programs were investigated for method. At the end of
this investigation, the temperature program of the GC–MS
was as follows: initial temperature was 150 C, held for
1 min, increased to 250 C at a rate of 30 C/min held for
1 min, and ﬁnally to 300 C at a rate of 10 C/min and held
for 1 min. The effects of time and temperature on the reaction
were investigated. To conﬁrm the complete derivatization offen in pharmaceutical preparations by GC–MS. Arabian Journal of Chemistry
Figure 1 The effect of reaction time and temperature on
derivatization reaction.
Figure 3 GC–MS chromatograms of ﬂurbiprofen (a) and
derivatized ﬂurbiprofen (b) (scan ion monitoring mode).
Figure 4 GC–MS chromatograms of ﬂurbiprofen (0.25, 0.5, 1, 2,
3, 4 and 5.0 lg/mL) [selected ion monitoring (SIM) mode, m/z 180
for ﬂurbiprofen].
Determination of ﬂurbiprofen in pharmaceutical preparations 3ﬂurbiprofen, since only one peak appears on the chromato-
gram, ﬂurbiprofen compound was derivatized and analyzed.
After establishing the optimum reaction conditions, the com-
pound was derivatized for analysis. To 100 lL of 1000 ng/mL
ﬂurbiprofen and 100 lL of MSTFA solution was added and
reacted at room temperature, 50, 70 and 80 C for 15, 30, 45
and 60 min. The resulting samples were quantitated by
GC–MS system. The effects of the time and temperature were
shown in Fig. 1.
3.2. Validation of the methods
To evaluate the validation of the present method, parameters
such as speciﬁcity, linearity, precision, accuracy, limit of
detection (LOD), limit of quantiﬁcation (LOQ), recovery and
stability were investigated according to ICH validation guide-
lines (ICH, 1996).
3.2.1. Speciﬁcity
The speciﬁcity of the method was investigated by observing
interferences between ﬂurbiprofen and the excipients. For
GC–MS, electron impact mode with selected ion monitoring
(SIM) was used for quantitative analysis (m/z 180 for ﬂurbi-
profen). The mass spectra of the ﬂurbiprofen are shown in
Fig. 2.
The retention time of ﬂurbiprofen for GC–MS was approx-
imately 5.5 min with good peak shape in scan and SIM mode
(Figs. 3 and 4).Figure 2 MS spectra after derivatization of ﬂurbiprofen with
MSTFA.
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The linearity of peak area response versus concentration
for ﬂurbiprofen was studied between concentration range
of 0.25–5.0 lg/mL. The calibration curve constructed was
evaluated by its correlation coefﬁcient. The calibration
equation from six replicate experiments, y= 2532.3x+ 186.52
(r= 0.996), demonstrated the linearity of the method. Standard
deviations of the slope and intercept for the calibration curves
were 1.5275 and 4.5832, respectively (Table 1).
A one-way analysis of variance (ANOVA) test (Duncan
et al., 1983; Bolton, 1997) was performed based on the values
observed for each pure drug concentration during the replicate
measurement of the standard solutions. The calculated F-value
(Fcalc) was found to be less than the critical F-value (Fcrit) at
5% signiﬁcance levels (Table 2).
3.2.3. Precision and accuracy
The precision of the analytic method was determined by
repeatability (within-day) and intermediate precisionfen in pharmaceutical preparations by GC–MS. Arabian Journal of Chemistry
Table 1 Linearity of ﬂurbiprofen.
Method Range (lg/mL) LRa Sa Sb R LOD (lg/mL) LOQ (lg/mL)
GC–MS 0.25–5.0 y= 2532.3x+ 186.52 1.5275 4.5832 0.996 0.05 0.15
Sb: standard deviation of slope of regression line, R: coefﬁcient of correlation, y: peak area, x: ﬂurbiprofen.
LOD: limit of detection, LOQ: limit of quantiﬁcation.
a Based on six calibration curves, LR: linear regression, Sa: standard deviation of intercept of regression line.
Table 2 One-way ANOVA test for linearity of pure ﬂurbiprofen solution by the proposed method.
Method Source of variation Degree of freedom Sum of squares Mean sum of squares F-value
Fcalc Fcrit
GC–MS Between groups 4 6.1264 · 103 3.1243 · 103
Within group 30 6.2109 · 108 1.3254 · 107 0.9999 2.6896a
Total 34 6.2112 · 108
a Theoretical value of F (4, 30) based on one-way ANOVA test at P= 0.05 level of signiﬁcance.
Table 3 Precision and accuracy of ﬂurbiprofen.
Method Added (lg/mL) Intra-day Inter-day
Found ± SD Accuracy Precision RSD %a Found ± SD Accuracy Precision RSD %a
GC–MS 0.75 0.74 ± 0.017 1.33 2.30 0.77 ± 0.028 2.67 3.64
2.50 2.49 ± 0.066 0.40 2.65 2.48 ± 0.086 0.80 3.47
4.50 4.48 ± 0.054 0.44 1.21 4.47 ± 0.072 0.67 1.61
SD: standard deviation of six replicate determinations, RSD: relative standard deviation
a Average of six replicate determinations, accuracy: (% relative error) (found-added)/addedx100.
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quality control samples (0.75, 2.5, 4.5 lg/mL) were analyzed
six times in one day for within-day precision and once daily
for three days for between-day precision. The RSD value for
within-day precision was 61.21% and for between-day preci-
sion was 63.64%. The bias value for within-day accuracy
was 60.40% and for between-day accuracy was 62.67%.
These values are summarized in Table 3.
3.2.4. Recovery
To determine the accuracy of the proposed method and to
study the interference of formulation additives, the recovery
was checked as three different concentration levels (0.5, 1.5,
3.5 lg/mL) and analytical recovery experiments were per-
formed by adding known amount of pure drugs to pre-
analyzed samples of commercial dosage forms. The percent
analytical recovery values were calculated by comparing con-
centration obtained from the spiked samples with actual added
concentrations. These values are also listed in Table 4.
3.2.5. Limit of detection and quantiﬁcation
The limit of detection (LOD) and limit of quantiﬁcation
(LOQ) were evaluated by serial dilutions of ﬂurbiprofen stock
solutions in order to obtain signal to noise ratios of 3:1 for
LOD and 10:1 for LOQ. The LOD and LOQ values for ana-
lyte were found to be 0.05 and 0.15 lg/mL, respectively
(Table 1).Please cite this article in press as: Yilmaz, B., Alkan, E. Determination of ﬂurbipro
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Stability studies indicated that the samples were stable when
kept at room temperature, +4 C and 20 C refrigeration
temperature for 24 h (short-term) and refrigerated at +4 and
20 C for 72 h (long-term). The results of these stability stud-
ies are given in Table 5, where the percent ratios are within the
acceptance range of 90–110%.
3.2.7. Ruggedness
In this study, GC–MS determination of ﬂurbiprofen was
carried out by a different analyst in same instrument with
the same standard (Table 6). The results showed no statistical
differences between different operators suggesting that the
developed method was rugged.4. Discussion
Today, GC–MS and HPLC methods are important and widely
used as analytical techniques of qualitative and quantitative
analysis. As compared to HPLC, high-resolution capillary
GC–MS has inherently high resolving power and high sensitiv-
ity with excellent precision and accuracy (Yilmaz et al., 2009).
GC–MS method sensitivity is not enough for the determi-
nation of ﬂurbiprofen in solution medium. For this reason,
MSTFA was chosen as a chromagenic derivatization reagent.
In this study, the purpose of the derivatization reaction isfen in pharmaceutical preparations by GC–MS. Arabian Journal of Chemistry
Table 4 Recovery of ﬂurbiprofen in pharmaceutical preparations.
Method Pharmaceutical preparation Added (lg/mL) Intra-day Inter-day
Found ± SD Recovery (%) RSDa (%) Found ± SD Recovery (%) RSDa (%)
GC–MS Majezik (0.50 lg/mL) 0.50 0.49 ± 0.016 98.0 3.27 0.49 ± 0.019 98.0 3.88
1.50 1.48 ± 0.041 98.7 2.77 1.49 ± 0.071 99.3 4.77
3.50 3.51 ± 0.145 100.3 4.13 3.47 ± 0.178 99.1 5.13
Frolix (0.50 lg/mL) 0.50 0.49 ± 0.010 98.0 3.27 0.49 ± 0.021 98.0 4.29
1.50 1.49 ± 0.041 99.3 2.75 1.49 ± 0.079 99.3 5.30
3.50 3.52 ± 0.144 100.6 4.13 3.47 ± 0.175 99.1 5.04
Maximus (0.50 lg/mL) 0.50 0.51 ± 0.025 98.0 4.09 0.49 ± 0.018 98.0 3.67
1.50 1.49 ± 0.039 99.3 2.60 1.49 ± 0.073 99.3 4.89
3.50 3.52 ± 0.158 100.6 4.51 3.47 ± 0.184 99.1 5.13
Zero-P (0.50 lg/mL) 0.50 0.49 ± 0.012 98.0 2.40 0.49 ± 0.012 98.0 3.30
1.50 1.47 ± 0.046 98.0 3.13 1.49 ± 0.049 99.3 3.29
3.50 3.53 ± 0.157 100.9 4.44 3.52 ± 0.145 100.6 4.12
Fortine (0.50 lg/mL) 0.50 0.51 ± 0.015 102.0 2.94 0.49 ± 0.017 98.0 3.47
1.50 1.48 ± 0.056 98.7 3.78 1.48 ± 0.046 98.7 3.11
3.50 3.49 ± 0.152 100.3 4.36 3.51 ± 0.149 100.3 4.24
SD: standard deviation of six replicate determinations, RSD: relative standard deviation.
a Average of six replicate determinations.
Table 5 Stability of ﬂurbiprofen in solution.
Stability (%) Room temperature stability Refrigeratory stability +4 C Frozen stability 20 C
Method Added (lg/mL) (Recovery %±RSD) (Recovery %±RSD) Recovery %± RSD
8 h 24 h 24 h 72 h 24 h 72 h
GC–MS 0.5 101.2 ± 3.84 101.8 ± 5.34 98.3 ± 3.12 99.2 ± 4.13 102.2 ± 5.38 98.4 ± 4.09
2.5 102.1 ± 6.43 99.1 ± 2.58 98.2 ± 3.25 98.6 ± 3.42 102.3 ± 3.84 991.2 ± 2.94
5.0 101.3 ± 3.87 98.2 ± 4.46 101.4 ± 4.42 98.4 ± 5.24 99.2 ± 5.46 102.4 ± 5.62
RSD: relative standard deviation of six replicate determinations.
Table 6 The results of analyses of standard ﬂurbiprofen by different analyst.a
Method Added (lg/mL) Intra-day Inter-day
Found ± SD Recovery (%) RSDa (%) Found ± SD Recovery (%) RSDa (%)
GC–MS 0.50 0.49 ± 0.012 98.0 2.45 0.49 ± 0.016 98.0 3.27
1.50 1.49 ± 0.039 99.3 2.62 1.49 ± 0.058 99.3 3.89
3.50 3.53 ± 0.136 100.9 3.85 3.52 ± 0.142 100.6 4.03
a Average of six replicate determinations.
Determination of ﬂurbiprofen in pharmaceutical preparations 5the raise of sensitivity thus the possibility of working in low
concentrations has been occurred.
A study of some potential interfering substances in the GC
determination of ﬂurbiprofen was performed by selecting them
as the excipients often used in pharmaceutical preparation
formulations. Samples containing a ﬁxed amount of the
ﬂurbiprofen (1.0 lg/mL) and variable concentrations of
excipients (lactose, starch, avicel, povidone, sodium dodecyl-
sulfate, aerosil and magnesium stearate) were measured.
All the results obtained by using the method described above
were compared with each other and no signiﬁcant difference
was observed between the amount of drugs found as
theoretical values for t at P= 0.05 level for commercial
formulations.
Pharmacopoeias (USP, 2000; BP, 1993 and IP, 1996) have
reported titrimetric and liquid chromatographic methods forPlease cite this article in press as: Yilmaz, B., Alkan, E. Determination of ﬂurbipro
(2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.038the analysis of ﬂurbiprofen in pure form and in pharmaceutical
formulations. Titrimetric method involves dissolving about
0.5 g of accurately weighed ﬂurbiprofen in 100 mL of alcohol
(previously neutralized with 0.1 M sodiumhydroxide versus
to the phenolphthalein end point) and then, titrating the same
(after adding phenolphthalein) with 0.1 M sodium hydroxide
versus till the ﬁrst appearance of faint pink color that persists
for not less than 30 s. Each ml of 0.1 M sodium hydroxide is
equivalent to 24.43 mg of ﬂurbiprofen. Other method has
recommended liquid chromatographic (HPLC) method for
analysis of related substances in pure ﬂurbiprofen and assay
of ﬂurbiprofen in pharmaceutical dosage form (tablet and oph-
thalmic drop). The methods recommended use a mobile phase
of water–acetonitrile–glacial acetic acid (60:35:5, v/v) at a ﬂow
rate of 1 mL/min, using UV detection (254 nm) on a stainless
steel column (4 lm, 3.9 · 15 cm i.d.).fen in pharmaceutical preparations by GC–MS. Arabian Journal of Chemistry
Table 7 Application of the method for the determination of ﬂurbiprofen in pharmaceutical preparations.
Method Pharmaceutical
preparation
n Found ± SD (mg) % RSD % Recovery F-test
GC–MS Majezik 10 99.1 ± 2.861 2.89 99.1
Frolix 10 99.6 ± 3.065 3.08 99.6
Maximus 10 100.1 ± 2.432 2.43 100.1 5.1a
Zero-P 10 98.6 ± 2.362 2.39 98.6
Fortine 10 99.4 ± 3.153 3.17 99.4
n: Number of determination, SD: standard deviation, RSD: relative standard deviation.
Ho hypothesis: no statistically signiﬁcant difference exists between ﬁve pharmaceutical preparations.
Ho hypothesis is accepted (P> 0.05).
a Theoretical values at P= 0.05.
6 B. Yilmaz, E. AlkanAlthough HPLC has been utilized in these studies, there
have been several problems. For example, retention times of
16 min (Hutzler et al., 2000) and 7.1 min (Han et al., 2008)
for the compound of interest may be considered excessive
when it is necessary to analyze multiple samples. The method
uses the rapid run time of 6 min. Hence, this method can be
used for the analysis of large number of samples.
A survey of literature reveals that no GC–MS method for
determination of ﬂurbiprofen in pharmaceutical preparations.
The present work describes the validation parameters stated
either by USP 26 (USP, 2000) or by the ICH guideline (ICH,
1996) and BP 1993 (BP, 1993) to achieve GC–MS method
for determination of ﬂurbiprofen.
The main objective of the validation of the developed GC–
MS method is to obtain the consistent, reliable and accurate
data. Validation of the developed the method plays its fore-
most role to achieve these goals. The results obtained from
the validation of developed method may be used to verify
the quality, quantity, accuracy and consistency of the active
pharmaceutical ingredient in pharmaceutical preparations.
We validated the developed method by performing linearity,
accuracy, precision, LOD and LOQ analysis. Linearity is used
to determine the response of different concentrations of ﬂurbi-
profen. We evaluated the developed method by detecting the
linearity using coefﬁcient of correlation (Table 1). From the
analysis of validation parameters, we found that the developed
method showed highest linearity (r> 0.996) in the range of
0.25–5.0 lg/mL. The calibration curve of ﬂurbiprofen was linear
over the concentration range of 0.25–5.0 lg/mL which is as
good as or superior to that reported in other papers (Hutzler
et al., 2000; Han et al., 2008; Rajani and Mukkanti, 2014).
The proposed method is very effective for the assay of ﬂur-
biprofen in ﬁve different tablets. The validity of the proposed
method was presented by recovery studies using the standard
addition method. For this purpose, a known amount of refer-
ence drug was spiked to formulated tablets and the nominal
value of drug was estimated by the proposed method. Each
level was repeated six times. The results were reproducible with
low SD and RSD. No interference from the common excipi-
ents was observed. The RSD for intra- and inter-day variation
was less than 3.64% for GC–MS method, which falls well
below the acceptance criteria described by Shah et al.,
(1992); Hutzler et al., (2000); Han et al., (2008). No internal
standard was used as no extraction step was involved in esti-
mation of ﬂurbiprofen in pharmaceutical preparations. Also,
the accuracy of the results established no need for internal
standard for the suggested method.Please cite this article in press as: Yilmaz, B., Alkan, E. Determination of ﬂurbipro
(2015), http://dx.doi.org/10.1016/j.arabjc.2014.12.038LOD and LOQ are the most important parameters for the
validation of the developed method. LOD is the lowest
amount of active ingredient present in the dosage form that
can be detected and it cannot be quantiﬁed as an exact value.
LOD is a point at which measured value is greater than the
uncertainty associated with it (Hutzler et al., 2000; Rajani
and Mukkanti, 2014). LOQ is the lowest amount of active
ingredient that can be quantitatively determined with accu-
racy. It is used to determine the quantity of the ingredient with
known concentrations by establishing the minimal level at
which the active ingredient can be quantiﬁed with suitable
accuracy and precision. In the present study, the value of
LOD was 0.05 lg/mL whereas for LOQ, it was 0.15 lg/mL.
The lowest values of LOD and LOQ made the developed
method more suitable for the analysis of ﬂurbiprofen in differ-
ent brands of ﬂurbiprofen tablets. The precision results of the
validated method were within the acceptable range (Table 3).
In comparison with earlier reported and ofﬁcial methods for
estimation of ﬂurbiprofen in pharmaceutical formulations
the proposed GC–MS method gave a lower LOD and LOQ
at 50 and 150 ng/mL when compared to 100 ng/mL and
1 mg/mL of two methods proposed earlier (Beaulieu et al.,
1991; Mathew et al., 1993). The proposed method also gave
a comparable or in most cases lower range of the calibration
plot. Unlike reported methods, the proposed method does
not utilize a special extraction step for recovering the drug
from the formulation excipients matrices thereby decreasing
the degree of error and time in estimation. The proposed
method of estimation of ﬂurbiprofen is, therefore, more accu-
rate and precise, rugged, reproducible and easier compared to
other reported methods. Also, the sample recoveries in all for-
mulations were in good agreement with their respective label
claims and thus suggested the validity of the methods and
non-interference of formulation excipients (Table 7).4. Conclusion
In the present report, a simple, rapid, sensitive, reliable, spe-
ciﬁc, accurate and precise GC–MS method for the determina-
tion of ﬂurbiprofen in pharmaceutical preparations was
developed and validated. The method described in the present
report has been effectively and efﬁciently used to analyze ﬂur-
biprofen pharmaceutical dosage forms without any interfer-
ence from the pharmaceutical excipients. Therefore, GC–MS
method can be used for the routine quality control analysis
of ﬂurbiprofen in pharmaceutical preparations. Also, thefen in pharmaceutical preparations by GC–MS. Arabian Journal of Chemistry
Determination of ﬂurbiprofen in pharmaceutical preparations 7method with its low detection level (50 ng/mL) can also be
used as an analytical tool for the cleaning validation studies
after batch change over in the industrial manufacturing area.
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